Growth Metrics

Moderna (MRNA) EPS (Basic) (2017 - 2025)

Moderna (MRNA) has disclosed EPS (Basic) for 9 consecutive years, with -$2.11 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 27.49% to -$2.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.27 through Dec 2025, up 21.66% year-over-year, with the annual reading at -$7.26 for FY2025, 21.77% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$2.11 at Moderna, down from -$0.51 in the prior quarter.
  • The five-year high for EPS (Basic) was $12.06 in Q4 2021, with the low at -$9.53 in Q3 2023.
  • Average EPS (Basic) over 5 years is $1.13, with a median of $0.12 recorded in 2023.
  • The sharpest move saw EPS (Basic) soared 2335.48% in 2021, then tumbled 1800.0% in 2025.
  • Over 5 years, EPS (Basic) stood at $12.06 in 2021, then tumbled by 68.08% to $3.85 in 2022, then plummeted by 85.45% to $0.56 in 2023, then crashed by 619.64% to -$2.91 in 2024, then increased by 27.49% to -$2.11 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$2.11, -$0.51, and -$2.13 for Q4 2025, Q3 2025, and Q2 2025 respectively.